DUBLIN--(BUSINESS WIRE)--The "Hepatitis B Vaccines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. 'Hepatitis B Vaccines: Global Strategic Business Report'
In the changed post COVID-19 business landscape, the global market for Hepatitis B Vaccines estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027. Combination Vaccines, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$2.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Mono Vaccines segment is readjusted to a revised 3.1% CAGR for the next 7-year period. The U.S. Market is Estimated at $715.6 Million, While China is Forecast to Grow at 6.5% CAGR
The Hepatitis B Vaccines market in the U.S. is estimated at US$715.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$668.6 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 3.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR. Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year
Influencer Market Insights
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS
4. GLOBAL MARKET PERSPECTIVE
For more information about this report visit https://www.researchandmarkets.com/r/oixc6p